Teva Pharmaceutical Industries (TEVA) Inventory (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Inventory for 18 consecutive years, with $3.2 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Inventory fell 7.89% year-over-year to $3.2 billion; the trailing twelve-month figure through Jun 2026 stood at $3.2 billion (down 7.89% YoY), and the FY2025 full-year result was $3.2 billion, up 5.72% from the prior year.
• Inventory improved to $3.2 billion in Q2 2026 per TEVA's latest filing, from $3.2 billion in the prior quarter.
• Across five years, Inventory topped out at $4.1 billion in Q1 2023 and bottomed at $3.0 billion in Q4 2024.
• Historically, Inventory has averaged $3.7 billion across 5 years, with a median of $3.9 billion in 2022.
• The sharpest annual moves came in 2024 and 2025: Inventory declined 25.22% in 2024, then gained 5.72% in 2025.
• Over 5 years, Inventory stood at $3.8 billion in 2022, then rose by 4.9% to $4.0 billion in 2023, then fell by 25.22% to $3.0 billion in 2024, then advanced by 5.72% to $3.2 billion in 2025, then rose by 1.32% to $3.2 billion in 2026.
• According to Business Quant data, Inventory over the past three periods registered $3.2 billion, $3.2 billion, and $3.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.